Examples of 'daclizumab' in a sentence
Meaning of "daclizumab"
daclizumab (adjective) - describing a medication or treatment that involves the use of the drug Daclizumab, often in a medical context
Show more definitions
- A humanized monoclonal antibody used to prevent rejection in organ transplantation, especially in kidney transplants.
How to use "daclizumab" in a sentence
Basic
Advanced
daclizumab
Daclizumab belongs to a group of medicines called immunosuppressants.
Zinbryta contains the active substance daclizumab.
Symptoms of a daclizumab overdose are not known.
The active substance is daclizumab beta.
Daclizumab was not genotoxic in standard tests.
Carcinogenicity studies with daclizumab have not been conducted.
Daclizumab appeared to be relatively well tolerated.
We contacted researchers participating in trials on daclizumab.
An abbreviated dosing schedule of daclizumab was used in one of the studies.
Daclizumab has not been studied in patients with hepatic impairment.
Appreciable daclizumab serum levels.
Daclizumab has not been studied in patients with renal impairment.
It was acknowledged that the mechanism of action of daclizumab beta is complex.
Daclizumab was used to treat adults with relapsing forms of multiple sclerosis.
The exact metabolic pathway for daclizumab has not been characterised.
See also
Daclizumab is given intravenously right after the transplant and then discontinued.
The causal relationship between daclizumab beta and colitis is possible.
The three year patient survival rate was significantly different between placebo and daclizumab in the.
No studies were conducted to evaluate daclizumab pharmacokinetics in patients with renal or hepatic impairment.
Autoimmune haemolytic anemia is already known to be related to daclizumab beta treatment.
The causal relationship between daclizumab beta and sarcoidosis is considered possible.
The active substance in Zinbryta is daclizumab beta.
Daclizumab beta is hypothesized to exert its activity in MS through immunomodulatory mechanisms.
There are limited data from the use of daclizumab in pregnant women.
There was limited exposure in patients over 55 years of age in clinical studies with daclizumab.
The other two patients received thymoglobulin and daclizumab as induction therapy during the transplant.
In another embodiment, the antibody of interest is daclizumab.
Amino acid sequences of Daclizumab with various FcRn binding mutations.
In one embodiment, the antibody is daclizumab.
Biogen Idec is developing daclizumab in collaboration with Abbott.
The most commonly used drugs for induction are thymoglobulin, alemtuzumab, basiliximab and daclizumab.
As an IgG1 monoclonal antibody, daclizumab is not expected to undergo renal elimination.
Daclizumab pharmacokinetics are well described by a two-compartment model with first-order absorption and elimination.
Because of the blinding, patients treated with daclizumab also got such therapy.
Daclizumab is currently marketed under the trademark Zenapax ® for transplant indications only.
Elimination As an IgG1 monoclonal antibody, daclizumab beta is not expected to undergo renal elimination.
One of 18 monkeys had an anaphylactic reaction to daclizumab.
The PRAC concluded that daclizumab is associated with a potentially fatal risk of immune-mediated liver injury.
It contains the active substance daclizumab 5 mg / ml.
Daclizumab is a recombinant humanized monoclonal antibody, subclass IgG1.
The humanized anti-Tac antibody daclizumab is described and its sequence is set forth in U. S.
Daclizumab is a humanised anti-IL-2r antibody built by total gene synthesis using oligonucleotides.
One vial with 5 ml concentrate for solution for infusion contains 25 mg daclizumab.
Daclizumab is not expected to undergo renal elimination or metabolism by hepatic enzymes see section 4.2.
Zenapax 5 mg / ml concentrate for solution for infusion Daclizumab.
Appreciable daclizumab serum levels were maintained except in 2 out of 18 monkeys that developed anti-daclizumab antibodies.
Examples of IL-2 alpha receptor antagonists include, without limitation, daclizumab and basiliximab.
Ed Lactation Daclizumab is excreted in cynomolgus monkey milk see section 5.3.
Prevention / treatment allograft rejection Anti-CD25 daclizumab.
Daclizumab is produced in a mammalian cell line ( NS0 ) by recombinant DNA technology.
